{"doi":"10.1101/2022.02.15.22271017","title":"The use of hippocampal grading as a biomarker for early MCI","abstract":"Abstract INTRODUCTION Changes in the hippocampus are associated with both increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Most studies have examined the association between hippocampal changes and episodic memory, with many reporting a relationship between hippocampal measurements and global cognition. However, these studies often find associations only in the later stages of cognitive decline. The goal of this study was to examine if hippocampal grading is associated with global cognition in cognitively normal controls (NC), early MCI (eMCI), late (lMCI), and AD, and whether such associations differ across diagnostic cohorts. METHODS Data from 1620 Alzheimer’s Disease Neuroimaging Initiative older adults were examined in this study (495 NC, 262 eMCI, 545 lMCI, and 318 AD). Participants were included if they completed baseline MRI scans and the Alzheimer’s disease Assessment Scale (ADAS-13) and Clinical Dementia Rating – Sum of Boxes (CDR-SB) cognitive tests. Linear regressions examined the influence of hippocampal grading on cognitive scores. RESULTS Lower global cognition (i.e., increased ADAS-13 scores) was associated with hippocampal grading scores in all cohorts, including normal controls. Lower global cognition (i.e., increased CDR-SB scores) was associated with hippocampal grading scores in lMCI and AD, but not in eMCI or NC groups. DISCUSSION These findings suggest that hippocampal grading is associated with changes in global cognition in NC, eMCI, lMCI, and AD depending on the cognitive test. Thus, hippocampal grading may be a useful measure that is sensitive to progressive changes early in the disease course.","journal":"medRxiv","year":2022,"id":302733,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9544,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":301640,"name":"Mahsa Dadar","orcid":"0000-0003-4008-2672","position":1,"is_corresponding":false},{"id":669804,"name":"Neda Shafiee","orcid":"0000-0002-1336-5231","position":2,"is_corresponding":false},{"id":194852,"name":"D. Louis Collins","orcid":"0000-0002-8432-7021","position":3,"is_corresponding":false},{"id":229339,"name":"Alzheimer’s Disease Neuroimaging Initiative","orcid":null,"position":4,"is_corresponding":false},{"id":669803,"name":"Cassandra Morrison","orcid":"0000-0002-1087-5770","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T00:32:20.348385Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}